• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves Medtronic’s Symplicity Spyral renal denervation system

FDA approves Medtronic’s Symplicity Spyral renal denervation system

November 17, 2023 By Jim Hammerand

Medtronic's Symplicity Spyral renal denervation catheter
Medtronic’s Symplicity Spyral renal denervation catheter [Image courtesy of Medtronic]
Medtronic (NYSE: MDT) today announced FDA approval of its Symplicity Spyral renal denervation (RDN) system for treating hypertension.

[Update: Read more of our coverage from the weeks following the approval, including Medtronic’s lessons learned, what’s next for the technology, and other potential applications.]

A Medtronic spokesperson said the device developer received word from regulators Friday evening. Medtronic is now the second company with premarket approval (PMA) to market an RDN system for hypertension in the U.S., following Recor Medical’s approval earlier this month.

Medtronic said it plans to immediately commercialize its system and the Symplicity blood pressure procedure.

Medtronic leaders have said RDN therapy could be a multibillion-dollar market, but it wasn’t clear whether the Spyral Symplicity system would get the green light from regulators.

This summer, medical and statistical experts on the FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee voted that the Spyral system’s risks outweighed its benefits. A day earlier, the same experts recommended approval of Recor Medical’s competing technology

A portrait of Jason Weidman, a Medtronic SVP and President of the Coronary and Renal Denervation business.
Jason Weidman is a Medtronic SVP and President of the Coronary and Renal Denervation business. [Photo courtesy of Medtronic]
“Medtronic has always believed in the potential of this therapy,” Medtronic SVP and Coronary and RDN President Jason Weidman said in a news release today. “We partnered closely with leading experts in our clinical community who could help us in our journey to get this technology to the people who need it most.”

“It was the promise of this therapy that enabled Medtronic to keep going, even when others exited the renal denervation space,” he continued. “High blood pressure is a global health issue, and patients need more options to manage their blood pressure. The approval of the Symplicity blood pressure procedure represents a significant milestone for physicians and patients in the treatment of hypertension.”

Medical Design & Outsourcing: Medtronic’s Jason Weidman explains renal denervation

More than 1.2 billion people worldwide are estimated to have hypertension, but most don’t have it under control, leading to heart attacks, strokes, kidney damage and premature deaths.

Medtronic’s minimally invasive system uses a four-electrode radiofrequency catheter inside the renal arteries to ablate overactive nerves in the artery walls, lowering blood pressure.

The FDA approved the Symplicity Spyral system “to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”

That indication is the same as the one the FDA approved for Recor Medical, but different than Medtronic’s proposed indication in its PMA submission.

Medtronic’s proposed indication was for “the reduction of blood pressure in patients with uncontrolled hypertension despite the use of anti-hypertensive medications or in patients in whom blood pressure lowering therapy is poorly tolerated.”

Experts on the FDA’s review panel took issue with that language as not closely enough linked to the results of Medtronic’s clinical studies. Medtronic’s clinical trials studying the safety and efficacy of its RDN technology over the years have failed to hit their primary endpoints for efficacy.

But Medtronic’s trials have demonstrated the system’s safety, making it a tough call for the FDA’s review panels.

Medical Design & Outsourcing: How Recor Medical won the renal denervation race for FDA approval

This post was originally published on Nov. 17, 2023, and updated with more RDN coverage in December 2023.

Filed Under: Cardiovascular, Catheters, Featured, Food & Drug Administration (FDA), News Well, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: FDA, Hypertension, Medtronic, RDN, renal denervation

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

About Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle, Washington, where he and his family live. Connect with him on LinkedIn or by email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy